VERA

Vera Therapeutics (NASDAQ:VERA) reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, marketed as TRUTAKNA, in adults with IgA nephropathy.

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk...

Vera Therapeutics recently announced that multiple company-sponsored abstracts, including final ORIGIN 3 efficacy data for TRUTAKNA in IgA nephropathy and interim PIONEER Phase 2 results, were presented as late-breaking sessions at ASN Kidney Week 2026 in…

ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgAN Will be A Featured Late-breaking Oral Presentation at Opening Plenary of ASN 2026

The expansion adds a harm-from-others safety area to VERA-MH, the first open-source AI safety benchmark for mental health, and invites public feedback ahead of Domestic Violence Awareness Month NEW YORK, Sept.

Vera Therapeutics (NasdaqGM: VERA) reported that TRUTAKNA met all prespecified endpoints in the final Phase III ORIGIN 3 trial for IgA nephropathy.

Vera stock reversed course Tuesday despite positive results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex.

Vera’s Trutakna was granted FDA accelerated approval in IgAN based on 36-week data.

Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.